Veraxa Biotech Holding AG Overview
Veraxa Biotech Holding AG (VRXA) has a ROE of -43.92%, below the sector sector average of -6.13%.
Get informed when a big investor buys or sells
+ Follow-43.92%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VRXA is -43.92%. That is below the sector sector average of -6.13%. Investors often review this figure alongside Veraxa Biotech Holding AG's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, VRXA currently prints -43.92% for ROE, while the sector average sits near -6.13%. That is roughly 616.7% below the sector mean. Large gaps often invite a closer look at Veraxa Biotech Holding AG's growth, margins, and balance sheet.
Return on Equity shows how effectively Veraxa Biotech Holding AG converts resources into returns. At -43.92%, VRXA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VRXA's ROE (-43.92%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
